ADX-850
- Generic Name
- ADX-850
Safety, Tolerability, PK and PD of ADX-850 in Participants with Hypertension
Phase 1
Recruiting
- Conditions
- Hypertension,EssentialHypertension
- Interventions
- First Posted Date
- 2024-01-16
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- ADARx Pharmaceuticals, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT06205628
- Locations
- 🇦🇺
CMAX Clinical Research, Adelaide, South Australia, Australia
🇦🇺Linear Clinical Research, Nedlands, Western Australia, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath